| 项目 | 不合并AIDs (n = 149) | 合并AIDs (n = 57) | p值 | ||
| 性别n,(%) |
|
|
|
| |
| 女性 |
| 45 (30.2) | 36 (63.2) | 0.000* | |
| 年龄n,(%) |
|
|
|
| |
| >60岁 |
| 82 (55.3) | 31 (55.4) | 0.995 | |
| WHO 2016 n, (%) | MDS-SLD | 5 (3.4) | 9 (15.8) | 0.003* | |
| MDS-MLD | 52 (34.9) | 25 (43.9) |
| ||
| MDS-EB1 | 36 (24.2) | 9 (15.8) |
| ||
| MDS-EB2 | 44 (29.5) | 11 (19.3) |
| ||
| MDS-RS-SLD | 1 (0.7) | 2 (3.5) |
| ||
| MDS-RS-MLD | 7 (4.7) | 1 (1.8) |
| ||
| 5q syndrome | 3 (2.0) | 0 (0) |
| ||
| MDS-U | 1 (0.7) | 0 (0) |
| ||
| IPSS n, (%) | 低危、中危1 | 81 (55.1) | 40 (70.2) | 0.046* | |
| 中危2、高危 | 66 (44.9) | 17 (29.8) |
| ||
| IPSS-R n, (%) | 极低危 | 5 (3.4) | 2 (3.5) | 0.075 | |
| 低危 | 23 (15.8) | 12 (21.1) |
| ||
| 中危 | 36 (24.7) | 21 (36.8) |
| ||
| 高危 | 44 (30.1) | 11 (19.3) |
| ||
| 极高危 | 38 (26) | 11 (19.3) |
| ||
| WPSS n, (%) | 极低危 | 1 (0.7) | 1 (1.8) | 0.111 | |
| 低危 | 12 (8.2) | 11 (19.3) |
| ||
| 中危 | 46 (31.5) | 17 (29.80) |
| ||
| 高危 | 68 (46.6) | 21 (36.8) |
| ||
| 极高危 | 19 (13) | 7 (12.3) |
| ||
| 染色体核型n, (%) | 好 | 77 (53.5) | 27 (51.9) | 0.956 | |
| 中 | 45 (31.3) | 18 (34.6) |
| ||
| 差 | 22 (15.3) | 7 (13.5) |
| ||
| 骨髓纤维化分级n, (%) | 0~1级 | 103 (79.2) | 43 (86.0) | 0.206 | |
| 2~3级 | 27 (20.8) | 7 (14.0) |
| ||
| 骨髓原始细胞(±标准差) |
| 6.51 (±0.52) | 4.79 (±0.77) | 0.075 | |
| 血沉(±标准差) |
| 38.71 (±6.2) | 57.17 (±4.9) | 0.020* | |
| 中位随访时间(四分位数) |
| 17.6 (10.4,32.2) | 25 (12,53.6) | 0.020* | |